LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article: Cannabinoid Hyperemesis

Pergolizzi Jr., Joseph V. / LeQuang, Jo Ann / Bisney, John F.

2018 Volume 1, Issue 2, Page(s) 73–95

Abstract: Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which a long-term cannabis user suffers an episode of intractable vomiting that may last days separated by longer asymptomatic periods of weeks or months. Cannabinoids are often ... ...

Institution	NEMA Research, Inc., Naples, Florida, USA
Abstract	Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which a long-term cannabis user suffers an episode of intractable vomiting that may last days separated by longer asymptomatic periods of weeks or months. Cannabinoids are often utilized for their antiemetic properties, so CHS can be a puzzling condition, and the diagnosis of CHS may be disputed by patients. Unlike other cyclic vomiting syndromes, CHS can be relieved by hot showers or topical capsaicin. Abstinence from cannabinoids causes CHS to resolve, sometimes in a matter of days or hours. Marijuana users as well as many clinicians are not aware of CHS, and patients may undergo unnecessary tests, scans, and other procedures to get an accurate diagnosis. Symptoms may be severe enough to require hospitalization. With liberalization of marijuana laws and favorable public opinion about the healing properties of cannabis, CHS may be more frequently observed in clinical practice.
Keywords	Cannabis ; Marijuana ; Cannabinoid hyperemesis ; Cannabinoid vomiting syndrome ; Hyperemesis ; Cyclic vomiting
Language	English
Publishing date	2018-11-15
Publisher	S. Karger AG
Publishing place	Basel, Switzerland
Document type	Article
Note	Basic Science – Review Article ; This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
ZDB-ID	2908431-3
ISSN	2504-3889 ; 2504-3889
ISSN (online)	2504-3889
ISSN	2504-3889
DOI	10.1159/000494992
Database	Karger publisher's database

Full text online

Full text

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- Full text online
- Order with fees

Article ; Online: Good clinical practice guide for opioids in pain management

Flaminia Coluzzi / Robert Taylor Jr. / Joseph V. Pergolizzi Jr. / Consalvo Mattia / Robert B. Raffa

Revista Brasileira de Anestesiologia, Vol 66, Iss 3, Pp 310-

the three Ts - titration (trial), tweaking (tailoring), transition (tapering)

2016 Volume 317

Abstract: ABSTRACT BACKGROUND AND OBJECTIVES: Achieving good clinical practice in the use of opioids as part of a comprehensive pain management regimen can face significant challenges. Despite guidelines from governmental and pain society/organization sources, ... ...

Abstract	ABSTRACT BACKGROUND AND OBJECTIVES: Achieving good clinical practice in the use of opioids as part of a comprehensive pain management regimen can face significant challenges. Despite guidelines from governmental and pain society/organization sources, there are still significant hurdles. A review of some basic tenets of opioid analgesia based on current published knowledge and experiences about this important healthcare imperative is warranted. CONTENT: Consistent with guidelines, the literature supports using the lowest total opioid dose that provides adequate pain control with the fewest adverse effects. Titration (or trial) during opioid initiation is a way of starting low and going slow (and assessing the appropriateness of a specific opioid and formulation). Recognizing that multiple factors contribute to an individual's personal experience of pain, the physical, psychological, social, cultural, spiritual, pharmacogenomic, and behavioral factors of the individual patient should be taken into account (tweaking, or tailoring). Finally, for those patients for whom transition (tapering) from opioid is desired, doing so too rapidly can have negative consequences and minimization of problems during this step can be achieved by proper tapering. CONCLUSION: We conclude that a simultaneously aggressive, yet conservative, approach is advocated in the literature in which opioid therapy is divided into three key steps (the 3 T's): titration (or trial), tweaking (or tailoring), and transition (or tapering). Establishment of the 3 T's along with the application of other appropriate good medical practice and clinical experience/judgment, including non-pharmacologic approaches, can assist healthcare providers in the effort to achieve optimal management of pain.
Keywords	Tratamento da dor ; Opioide ; Titulação ; Ajuste ; Redução gradual ; Surgery ; RD1-811 ; Medicine ; R
Subject code	170
Language	English
Publishing date	2016-06-01T00:00:00Z
Publisher	Sociedade Brasileira de Anestesiologia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain

Pergolizzi Jr JV / Raffa RB

Journal of Pain Research, Vol Volume 12, Pp 3299-

2019 Volume 3317

Abstract: Joseph V Pergolizzi Jr,1,2 Robert B Raffa3,4 1NEMA Research, Inc., Naples, FL, USA; 2Neumentum ... of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USACorrespondence: Joseph V ... Pergolizzi JrNEMA Research, Inc., 868 106th Ave. North, Naples, FL 34108, USATel +1 239-597-3564Fax +1 239 ...

Abstract	Joseph V Pergolizzi Jr,1,2 Robert B Raffa3,4 1NEMA Research, Inc., Naples, FL, USA; 2Neumentum, Palo Alto, CA, USA; 3University of Arizona College of Pharmacy, Tucson, AZ, USA; 4Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USACorrespondence: Joseph V Pergolizzi JrNEMA Research, Inc., 868 106th Ave. North, Naples, FL 34108, USATel +1 239-597-3564Fax +1 239-908-4436Email jpjmd@msn.comBackground: Chronic pain is associated with decreased quality of life and is one of the most common reasons adults seek medical care, making treatment imperative for many aspects of patient well-being. Chronic pain management typically involves the use of Schedule II full μ-opioid receptor agonists for pain relief; however, the increasing prevalence of opioid addiction is a national crisis that is impacting public health and social and economic welfare. Buprenorphine is a Schedule III partial μ-opioid receptor agonist that is an equally effective but potentially safer treatment option for chronic pain than full μ-opioid receptor agonists. The purpose of this review is to provide an overview of the clinical efficacy and safety of the transdermal and buccal formulations of buprenorphine, which are approved by the Food and Drug Administration for chronic pain, compared with that of extended-release full μ-opioid receptor agonists.Methods: Controlled or randomized controlled clinical trial information was retrieved from EMBASE, Medline, and PubMed using the search terms “buprenorphine” AND “chronic” AND “pain.”Results: A total of 33 clinical studies were ultimately used in this review, including 29 (88%) on transdermal buprenorphine and 4 (12%) on buprenorphine buccal film. Although the measure of pain intensity varied among studies, each of these 33 trials demonstrated efficacy for buprenorphine in pain relief. A total of 28 studies also assessed safety, with each concluding that buprenorphine was generally well tolerated.Conclusion: Comparison of current clinical data along with results ...
Keywords	opioids ; schedule iii ; partial μ-opioid receptor agonist ; Medicine (General) ; R5-920
Subject code	616
Language	English
Publishing date	2019-12-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Long-term use of opioids in 210 officially registered patients with chronic noncancer pain in Taiwan

Tso-Chou Lin / Luo-Ping Ger / Joseph V. Pergolizzi, Jr. / Robert B. Raffa / Ju-O Wang / Shung-Tai Ho

Journal of the Formosan Medical Association, Vol 116, Iss 4, Pp 257-

A cross-sectional study

2017 Volume 265

Abstract: Prescribing opioids for chronic noncancer pain has been strictly regulated for two decades in Taiwan. The aim of this study was to survey the patients' perspectives and potential drawbacks following long-term use of opioids. Methods: An observational ... ...

Abstract	Prescribing opioids for chronic noncancer pain has been strictly regulated for two decades in Taiwan. The aim of this study was to survey the patients' perspectives and potential drawbacks following long-term use of opioids. Methods: An observational cross-sectional survey using the Taiwanese version of Brief Pain Inventory was conducted among outpatients with chronic noncancer pain registered by the Taiwan Food and Drug Administration. Patients were also asked about their sexual behavior, depression, opioid misuse behaviors, and use of complementary and alternative medicine. Results: For 210 of 328 outpatients (64.0%), the median pain duration was 96 months and opioid treatment duration was 57 months. The median morphine equivalent dose was 150 mg/d, with 30.5% of patients exceeding the daily watchful dose, defined as 200 mg of morphine equivalent dose. Pain reduction after taking opioids was ∼50% in the past week. The top three diagnoses were chronic pancreatitis, spinal cord injury, and neuralgia. The leading side effects were constipation (46.7%), and decreased sexual desire (69.5%) and satisfaction (57.9%). Depression was currently diagnosed in 55.2% of patients. Twenty patients (9.5%) displayed at least one aberrant behavior in the past month. Only 76 (36.2%) patients had ever received nerve block procedures, and 118 (56.2%) tried complementary and alternative medicine. Conclusion: This nationwide survey described the concurrent pain intensity, daily function, and various adverse effects by long-term opioids among 210 monitored outpatients with chronic noncancer pain in Taiwan. More efforts are suggested to reduce opioid prescriptions in the 30% of patients exceeding daily watchful dose.
Keywords	chronic pain ; noncancer ; opioid ; Medicine (General) ; R5-920
Subject code	616 ; 610
Language	English
Publishing date	2017-04-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Vitamin D and Number of Falls in a Long-Term Care Facility

Robert B. Raffa / Frank Breve / Robert Taylor Jr. / Joseph V. Pergolizzi Jr.

Pharmacology & Pharmacy, Vol 03, Iss 04, Pp 453-

2012 Volume 457

Abstract: Falls represent a significant contribution to the morbidity and mortality of the elderly population. Because vitamin D is important in bone physiology, the use of vitamin D to restore deficient bone and ameliorate the effects of bone fractures due to ... ...

Abstract	Falls represent a significant contribution to the morbidity and mortality of the elderly population. Because vitamin D is important in bone physiology, the use of vitamin D to restore deficient bone and ameliorate the effects of bone fractures due to falls has become a common practice in recent years. Following introduction of widespread use, reports began to emerge that vitamin D not only aided in repair of fall-induced bone fractures, but that it also reduced the occurrence of falls. Vitamin D now has become a routine intervention as a fall- prevention measure. Early analyses found evidence of prevention efficacy (reduced falls), but recent analyses are more equivocal. We retrospectively examined the records of 350 patients in a long-term care facility in which vitamin D administration and the number of falls were recorded as part of a comprehensive database of care. We found a dramatic rise in vitamin D use over the period covered (2006 – 2011) and a corresponding dramatic decrease in the number of falls. However, the number of falls continued to decline after 2008, despite a plateau in number of patients on vitamin D, particularly females. It appears that other factors contribute to the overall decline.
Keywords	Falls ; Bone Fracture ; Vitamin D ; Long-Term Care Facility ; Therapeutics. Pharmacology ; RM1-950 ; Medicine ; R ; DOAJ:Therapeutics ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Subject code	360
Language	English
Publishing date	2012-10-01T00:00:00Z
Publisher	Scientific Research Publishing
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Managing severe pain and abuse potential

Pergolizzi, J / Pergolizzi, Jr JV / Taylor Jr R / LeQuang JA / Raffa RB

Journal of Pain Research, Vol Volume 11, Pp 301-

the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product

2018 Volume 311

Abstract: Joseph V Pergolizzi, Jr,1 Robert Taylor Jr,1 Jo Ann LeQuang,1 Robert B Raffa2,3 On behalf ...

Abstract	Joseph V Pergolizzi, Jr,1 Robert Taylor Jr,1 Jo Ann LeQuang,1 Robert B Raffa2,3 On behalf of the NEMA Research Group 1NEMA Research Inc., Naples, FL, USA; 2University of Arizona College of Pharmacy, Tucson, AZ, USA; 3Temple University School of Pharmacy, Philadelphia, PA, USA Abstract: Proper management of severe pain represents one of the most challenging clinical dilemmas. Two equally important goals must be attained: the humanitarian/medical goal to relieve suffering and the societal/legal goal to not contribute to the drug abuse problem. This is an age-old problem, and the prevailing emphasis placed on one or the other goal has resulted in pendulum swings that have resulted in either undertreatment of pain or the current epidemic of misuse and abuse. In an effort to provide efficacious strong pain relievers (opioids) that are more difficult to abuse by the most dangerous routes of administration, pharmaceutical companies are developing products in which the opioid is manufactured in a formulation that is designed to be tamper resistant. Such a product is known as an abuse-deterrent formulation (ADF). ADF opioid products are designed to deter or resist abuse by making it difficult to tamper with the product and extracting the opioid for inhalation or injection. To date, less than a dozen opioid formulations have been approved by the US Food and Drug Administration to carry specific ADF labeling, but this number will likely increase in the coming years. Most of these products are extended-release formulations. Keywords: oxycodone/naltrexone, abuse-deterrent formulation, abuse-deterrent opioid, oxycodone, abuse liability
Keywords	oxycodone/naltrexone ; abuse-deterrent formulation ; abuse-deterrent opioid ; oxycodone ; abuse liability ; Medicine (General) ; R5-920
Subject code	360
Language	English
Publishing date	2018-02-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Transdermal Buprenorphine for Acute Pain in the Clinical Setting

Pergolizzi JV Jr / Magnusson P / LeQuang JA / Breve F / Mitchell K / Chopra M / Varrassi G

Journal of Pain Research, Vol Volume 14, Pp 871-

A Narrative Review

2021 Volume 879

Abstract: Joseph V Pergolizzi Jr,1 Peter Magnusson,2,3 Jo Ann LeQuang,1 Frank Breve,4 Kailyn Mitchell,1 ... Foundation, Rome, ItalyCorrespondence: Jo Ann LeQuangNEMA Research, Inc., 4005 Technology Drive, Suite 1008-V ...

Abstract	Joseph V Pergolizzi Jr,1 Peter Magnusson,2,3 Jo Ann LeQuang,1 Frank Breve,4 Kailyn Mitchell,1 Maninder Chopra,5 Giustino Varrassi6 1NEMA Research, Inc., Naples, FL, USA; 2Centre for Research and Development, Region Gävleborg/Uppsala University, Gävle, Sweden; 3Department of Medicine, Cardiology Research Unit, Karolinska Institutet, Stockholm, Sweden; 4Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA, USA; 5Decision Alternatives, LLC, Frederick, MD, USA; 6Paolo Procacci Foundation, Rome, ItalyCorrespondence: Jo Ann LeQuangNEMA Research, Inc., 4005 Technology Drive, Suite 1008-V, Angleton, TX, 77515, USATel +1-979-824-0251Email joannlequang@gmail.comAbstract: Transdermal buprenorphine is indicated for chronic pain management, but as its role in the clinical management of acute pain is less clear, this narrative review examines studies of the patch for acute pain, mainly in the postoperative setting. Although perhaps better known for its role in opioid rehabilitation programs, buprenorphine is also an effective analgesic that is a Schedule III controlled substance. Although buprenorphine is a partial agonist at the μ-opioid receptor, it is erroneous to think of the agent as a partial analgesic; it has full analgesic efficacy and unique attributes among opioids, such as a ceiling for respiratory depression and low “drug likeability” among those who take opioids for recreational purposes. Transdermal buprenorphine has been most thoroughly studied for acute pain control in postoperative patients. Postoperative pain follows a distinct and predictable trajectory depending on the type of surgery and patient characteristics. Overall, when the patch is applied prior to surgery and left in place for the prescribed seven days, it was associated with reduced postoperative pain, lower consumption of other analgesics, and patient satisfaction. Transdermal buprenorphine has been evaluated in clinical studies of patients undergoing gynecological surgery, hip fracture surgery, knee or hip ...
Keywords	acute pain control ; ceiling effect of buprenorphine ; geriatric pain patients ; gynecological surgery ; hip arthroscopy ; knee arthroscopy ; opioid-associated side effects ; orthopedic rehabilitation ; orthopedic surgery ; postoperative pain ; spinal surgery ; transdermal buprenorphine dosing ; Medicine (General) ; R5-920
Subject code	616
Language	English
Publishing date	2021-03-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

Pergolizzi Jr JV / Raffa RB / Pappagallo M / Fleischer C / Pergolizzi, III J / Zampogna G / Duval E / Hishmeh J / LeQuang JA / Taylor R Jr

Patient Preference and Adherence, Vol Volume 11, Pp 107-

2017 Volume 119

Abstract: Joseph V Pergolizzi Jr,1 Robert B Raffa,2,3 Marco Pappagallo,4 Charles Fleischer,1 Joseph ... Pergolizzi III,1 Gianpietro Zampogna,5 Elizabeth Duval,1 Janan Hishmeh,1 Jo Ann LeQuang,1 Robert Taylor Jr1 ...

Abstract	Joseph V Pergolizzi Jr,1 Robert B Raffa,2,3 Marco Pappagallo,4 Charles Fleischer,1 Joseph Pergolizzi III,1 Gianpietro Zampogna,5 Elizabeth Duval,1 Janan Hishmeh,1 Jo Ann LeQuang,1 Robert Taylor Jr1 1NEMA Research, Inc., Naples, FL, 2University of Arizona College of Pharmacy, University of Arizona, Tucson, AZ, 3Temple University School of Pharmacy, Temple University, Philadelphia, PA, 4Department of Medicine, Albert Einstein College of Medicine, New York, NY, 5Department of Medicine, St. Luke’s Hospital, Cleveland, OH, USA Abstract: Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting μ-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting μ-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone. Keywords: opioid-induced constipation, opioid bowel disorder, PAMORA, peripherally acting mu-opioid receptor antagonist, noncancer pain patients, opioid-associated side effects
Keywords	Opioid-induced constipation ; opioid bowel disorder ; chronic opioid therapy ; noncancer pain patients ; opioid-associated side effects ; Medicine (General) ; R5-920
Language	English
Publishing date	2017-01-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology

Pergolizzi Jr JV / Raffa RB / Fleischer C / Zampogna G / Taylor R Jr

Journal of Pain Research, Vol Volume 9, Pp 909-

2016 Volume 916

Abstract: Joseph V Pergolizzi Jr,1 Robert B Raffa,2,3 Charles Fleischer,1 Gianpietro Zampogna,1 Robert Taylor ...

Abstract	Joseph V Pergolizzi Jr,1 Robert B Raffa,2,3 Charles Fleischer,1 Gianpietro Zampogna,1 Robert Taylor Jr1 1NEMA Research, Naples, FL, 2University of Arizona College of Pharmacy, Tucson, AZ, 3Temple University School of Pharmacy, Philadelphia, PA, USA Abstract: With a global prevalence of ~9%–12%, low back pain (LBP) is a serious public health issue, associated with high costs for treatment and lost productivity. Chronic LBP (cLBP) involves central sensitization, a neuropathic pain component, and may induce maladaptive coping strategies and depression. Treating cLBP is challenging, and current treatment options are not fully satisfactory. A new BioErodible MucoAdhesive (BEMA®) delivery system for buprenorphine has been developed to treat cLBP. The buccal buprenorphine (BBUP) film developed for this product (Belbuca™) allows for rapid delivery and titration over a greater range of doses than was previously available with transdermal buprenorphine systems. In clinical studies, BBUP was shown to effectively reduce pain associated with cLBP at 12weeks with good tolerability. The most frequently reported side effects with the use of BBUP were nausea, constipation, and vomiting. There was no significant effect on the QT interval vs placebo. Chronic pain patients using other opioids can be successfully rotated to BBUP without risk of withdrawal symptoms or inadequate analgesia. The role of BBUP in managing cLBP remains to be determined, but it appears to be a promising new product in the analgesic arsenal in general. Keywords: buccal, transmucosal, buprenorphine, chronic low back pain, BEMA, drug delivery Belbuca
Keywords	Buccal ; transmucosal ; buprenorphine ; chronic low back pain ; BEMA ; drug delivery ; Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2016-10-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis

Taylor Jr R, Raffa RB / Pergolizzi Jr JV

Journal of Pain Research, Vol 2012, Iss default, Pp 77-

a critical review of the literature

2012 Volume 87

Abstract: Robert Taylor Jr1, Robert B Raffa2, Joseph V Pergolizzi Jr3–51NEMA Research Inc, Naples, FL ...

Abstract	Robert Taylor Jr1, Robert B Raffa2, Joseph V Pergolizzi Jr3–51NEMA Research Inc, Naples, FL; 2Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 3Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 4Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; 5Department of Anesthesiology, Georgetown University School of Medicine, Washington, DC, USAAbstract: Osteoarthritis (OA) is a physically and emotionally debilitating disease that predominantly affects the aging adult population. Current pharmacologic treatment options primarily consist of nonsteroidal anti-inflammatory drugs and/or acetaminophen, but associated side effects, analgesic limitations, especially in the elderly, and the need for around-the-clock analgesia have led physicians to search for alternative analgesics. Opioids have shown effectiveness at mitigating both chronic cancer and noncancer pain, and their ability to be placed into controlled release (CR) formulations suggests that they may prove efficacious for OA patients. One formulation, oxycodone CR, has shown effectiveness in cancer pain patients and in some trials of noncancer low back pain. In this review, the objective was to synthesize the reported findings by researchers in this field and present an up-to-date look at the efficacy, safety, and tolerability of oxycodone CR in OA patients. Public literature databases were searched using specific keywords (eg, oxycodone CR) for studies assessing the efficacy and safety profile of oxycodone CR and its use in patients with OA. A total of eleven articles that matched the criteria were identified, which included three placebo-controlled trials, six comparative trials, one pharmacokinetic study in the elderly, and one long-term safety trial. Analysis of the studies revealed that oxycodone CR is reasonably efficacious, safe, and tolerable when used to manage moderate to severe chronic OA pain, with similar side effects to that of other ...
Keywords	Medicine (General) ; R5-920
Subject code	610
Language	English
Publishing date	2012-04-01T00:00:00Z
Publisher	Dove Medical Press
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED